Camilla Djenne Buarque

Prof. Camilla Djenne Buarque

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2016 in ChemCatChem
Verified
Journal Article
Closed access
PDF file
RGRaoni S. B. Gonçalves
Raoni S. B. Gonçalves
AOAlline B. V. de Oliveira
Alline B. V. de Oliveira
HSHaryadylla C. Sindra
Haryadylla C. Sindra
BABraulio S Archanjo
Braulio S Archanjo
MMMartín E. Mendoza
Martín E. Mendoza
PEPierre M. Esteves
Pierre M. Esteves

1 March 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
VSVeronica D. da Silva
Veronica D. da Silva
BFBruna M. de Faria
Bruna M. de Faria
ECEduardo Colombo
Eduardo Colombo
LALucas Ascari
Lucas Ascari
GFGabriella P.A. Freitas
Gabriella P.A. Freitas
Camilla Djenne BuarqueCamilla Djenne Buarque
Camilla Djenne Buarque

12 May 2021 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
JMJoseane A Mendes
Joseane A Mendes
PCPaulo R. R. Costa
Paulo R. R. Costa
MYMiguel Yus
Miguel Yus
FFFrancisco Foubelo
Francisco Foubelo
Camilla Djenne BuarqueCamilla Djenne Buarque
Camilla Djenne Buarque
The synthesis of nitrogen-containing heterocycles, including natural alkaloids and other compounds presenting different types of biological activities have proved to be successful employing chiral sulfinyl imines derived from tert-butanesulfinamide. These imines are versatile chiral auxiliaries and have been extensively used as eletrophiles in a wide range of reactions. The electron-withdrawing sulfinyl group facilitates the nucleophilic addition of organometallic compounds to the iminic carbon with high diastereoisomeric excess and the free amines obtained after an easy removal of the tert-butanesulfinyl group can be transformed into enantioenriched nitrogen-containing heterocycles. The goal of this review is to the highlight enantioselective syntheses of heterocycles involving the use of chiral N-tert-butanesulfinyl imines as reaction intermediates, including the synthesis of several natural products. The synthesis of nitrogen-containing heterocycles in which the nitrogen atom is not provided by the chiral imine will not be considered in this review. The sections are organized according to the size of the heterocycles. The present work will comprehensively cover the most pertinent contributions to this research area from 2012 to 2020. We regret in advance that some contributions are excluded in order to maintain a concise format.

22 March 2018 in Topics in Catalysis
Verified
Journal Article
Closed access
PDF file
JCJhonny M. C. Cifuentes
Jhonny M. C. Cifuentes
BFBruno X. Ferreira
Bruno X. Ferreira
PEPierre M. Esteves
Pierre M. Esteves
Camilla Djenne BuarqueCamilla Djenne Buarque
Camilla Djenne Buarque

29 September 2020 in Journal of Applied Crystallography
Verified
Journal Article
Closed access
PDF file
Renata Avena MaiaRenata Avena Maia
Renata Avena Maia
LCLeonardo Simões de Abreu Carneiro
Leonardo Simões de Abreu Carneiro
JCJhonny Mauricio Cerón Cifuentes
Jhonny Mauricio Cerón Cifuentes
Camilla Djenne BuarqueCamilla Djenne Buarque
Camilla Djenne Buarque
PEPierre M. Esteves
Pierre M. Esteves
Ana Maria PercebomAna Maria Percebom
Ana Maria Percebom

10 February 2024 in Molecules
Verified
Journal Article
Open access
PDF file
FFFilipa Castela Ferreira
Filipa Castela Ferreira
Camilla Djenne BuarqueCamilla Djenne Buarque
Camilla Djenne Buarque
Miquéias Lopes-PachecoMiquéias Lopes-Pacheco
Miquéias Lopes-Pacheco
The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells. The discovery and subsequent development of CFTR modulators—small molecules acting on the basic molecular defect in CF—have revolutionized the standard of care for people with CF (PwCF), thus drastically improving their clinical features, prognosis, and quality of life. Currently, four of these drugs are approved for clinical use: potentiator ivacaftor (VX-770) alone or in combination with correctors lumacaftor, (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). Noteworthily, the triple combinatorial therapy composed of ivacaftor, tezacaftor, and elexacaftor constitutes the most effective modulator therapy nowadays for the majority of PwCF. In this review, we exploit the organic synthesis of ivacaftor, tezacaftor, and elexacaftor by providing a retrosynthetic drug analysis for these CFTR modulators. Furthermore, we describe the current understanding of the mechanisms of action (MoA’s) of these compounds by discussing several studies that report the key findings on the molecular mechanisms underlying their action on the CFTR protein.